{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:53:43Z","timestamp":1792670023501,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016242","name":"Boston Scientific Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011027","name":"Kowa Pharmaceutical Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023405","name":"Japan Research Promotion Society for Cardiovascular Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.atherosclerosis.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:38:16Z","timestamp":1589805496000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome"],"prefix":"10.1016","volume":"303","author":[{"given":"Mayui","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Arashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib1","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib3","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib5","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/S0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"86","author":"Boden","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/hrt.2011.225466","article-title":"High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention","volume":"97","author":"Seo","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2013.04.101","article-title":"Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication","volume":"62","author":"van de Woestijne","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/eurheartj\/ehi186","article-title":"High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2012.01.029","article-title":"The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction","volume":"163","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2015.05.010","article-title":"High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: a report from the CREDO-Kyoto registry cohort-2","volume":"242","author":"Izuhara","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib13","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/eurheartj\/eht343","article-title":"High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality","volume":"34","author":"Silbernagel","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib14","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2018.04.036","article-title":"Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: a sub-analysis of HIJ-PROPER","volume":"274","author":"Yamaguchi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2007.11.075","article-title":"Lipid levels after acute coronary syndromes","volume":"51","author":"Pitt","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/ATVBAHA.108.178681","article-title":"HDL remodeling during the acute phase response","volume":"29","author":"Jahangiri","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.amjcard.2017.07.043","article-title":"Effect of body mass index on clinical events after acute coronary syndromes","volume":"120","author":"Lamelas","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.amjcard.2018.08.028","article-title":"Predictive value of baseline high-sensitivity C-reactive protein level and renal function for patients with acute coronary syndrome undergoing aggressive lipid-lowering therapy: a subanalysis of HIJ-PROPER","volume":"122","author":"Kawada-Watanabe","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22, Arterioscler","volume":"29","author":"Ray","year":"2009","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib23","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2017.05.001","article-title":"Patavastatin and HHDL: effects on plasma levels and function(s)","volume":"27","author":"Pirillo","year":"2017","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/2047487318820976","article-title":"Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: the end of a dream?","volume":"26","author":"Pirillo","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib26","first-page":"815","volume":"3","author":"Nicholls","year":"2018","journal-title":"Cardiol"},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib27","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-Thrive Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib29","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.05.005_bib31","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:06Z","timestamp":1762187106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020302586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":31,"alternative-id":["S0021915020302586"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.005","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}